Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

Agustoni F, Suda K, Yu H, Ren S, Rivard CJ, Ellison K, Caldwell C Jr, Rozeboom L, Brovsky K, Hirsch FR.

Cancer Treat Rev. 2019 Jan;72:15-27. doi: 10.1016/j.ctrv.2018.08.002. Epub 2018 Aug 4. Review.

PMID:
30445271
2.

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

Ren S, Tian Q, Amar N, Yu H, Rivard CJ, Caldwell C, Ng TL, Tu M, Liu Y, Gao D, Ellison K, Suda K, Rozeboom L, Rivalland G, Mitchell P, Zhou C, Hirsch FR.

Lung Cancer. 2018 Nov;125:115-120. doi: 10.1016/j.lungcan.2018.09.004. Epub 2018 Sep 12.

PMID:
30429008
3.

Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats.

Villegas LR, Rivard CJ, Hunter B, You Z, Roncal C, Joy MS, Le MT.

PLoS One. 2018 Nov 8;13(11):e0207024. doi: 10.1371/journal.pone.0207024. eCollection 2018.

4.

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.

Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.

J Thorac Oncol. 2019 Jan;14(1):25-36. doi: 10.1016/j.jtho.2018.09.006. Epub 2018 Sep 22.

PMID:
30253973
5.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.

Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.

Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28.

6.

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, Rozeboom L, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

Mol Cancer Ther. 2018 Oct;17(10):2257-2265. doi: 10.1158/1535-7163.MCT-17-1279. Epub 2018 Jul 26.

PMID:
30049789
7.

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions.

Suda K, Kim J, Murakami I, Rozeboom L, Shimoji M, Shimizu S, Rivard CJ, Mitsudomi T, Tan AC, Hirsch FR.

J Thorac Oncol. 2018 Oct;13(10):1496-1507. doi: 10.1016/j.jtho.2018.05.039. Epub 2018 Jun 19.

8.

Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study.

Rivard CJ, Tanabe T, Lanaspa MA, Watanabe H, Nomura S, Andres-Hernando A, Garth K, Sekijima M, Ishimoto T, Ariyoshi Y, Garcia GE, Shah J, Lennan B, Tasaki M, Pomposelli T, Shimizu A, Sachs DH, Johnson RJ, Yamada K.

Transpl Int. 2018 Oct;31(10):1164-1177. doi: 10.1111/tri.13273. Epub 2018 Jun 5.

9.

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules.

He Y, Yang Y, Kuang P, Ren S, Rozeboom L, Rivard CJ, Li X, Zhou C, Hirsch FR.

Onco Targets Ther. 2017 Dec 13;10:5915-5926. doi: 10.2147/OTT.S151432. eCollection 2017.

10.

MHC class II expression in lung cancer.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Lung Cancer. 2017 Oct;112:75-80. doi: 10.1016/j.lungcan.2017.07.030. Epub 2017 Jul 29.

PMID:
29191604
11.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

Genova C, Socinski MA, Hozak RR, Mi G, Kurek R, Shahidi J, Paz-Ares L, Thatcher N, Rivard CJ, Varella-Garcia M, Hirsch FR.

J Thorac Oncol. 2018 Feb;13(2):228-236. doi: 10.1016/j.jtho.2017.11.109. Epub 2017 Nov 20.

12.

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR.

Biomed Res Int. 2017;2017:7694202. doi: 10.1155/2017/7694202. Epub 2017 Oct 8.

13.

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.

Suda K, Rivard CJ, Mitsudomi T, Hirsch FR.

Expert Rev Anticancer Ther. 2017 Sep;17(9):779-786. doi: 10.1080/14737140.2017.1355243. Epub 2017 Jul 17. Review.

PMID:
28701107
14.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR.

Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19.

15.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Med Sci Monit. 2017 Mar 9;23:1208-1216.

16.

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.

Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jun;12(6):1015-1020. doi: 10.1016/j.jtho.2017.02.002. Epub 2017 Feb 11.

17.

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.

Suda K, Rozeboom L, Yu H, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

PLoS One. 2017 Feb 13;12(2):e0172209. doi: 10.1371/journal.pone.0172209. eCollection 2017.

18.

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.

J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.

19.

Heat stress, hydration and uric acid: a cross-sectional study in workers of three occupations in a hotspot of Mesoamerican nephropathy in Nicaragua.

Wesseling C, Aragón A, González M, Weiss I, Glaser J, Rivard CJ, Roncal-Jiménez C, Correa-Rotter R, Johnson RJ.

BMJ Open. 2016 Dec 8;6(12):e011034. doi: 10.1136/bmjopen-2016-011034. Erratum in: BMJ Open. 2017 Jan 25;7(1):e011034corr1.

20.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14.

21.

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. Review.

22.

Bioactivity-Guided Identification of Botanical Inhibitors of Ketohexokinase.

Le MT, Lanaspa MA, Cicerchi CM, Rana J, Scholten JD, Hunter BL, Rivard CJ, Randolph RK, Johnson RJ.

PLoS One. 2016 Jun 20;11(6):e0157458. doi: 10.1371/journal.pone.0157458. eCollection 2016.

23.

Lymphocyte-activation gene-3, an important immune checkpoint in cancer.

He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR.

Cancer Sci. 2016 Sep;107(9):1193-7. doi: 10.1111/cas.12986. Epub 2016 Aug 25. Review.

24.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation.

Suda K, Murakami I, Yu H, Ellison K, Shimoji M, Genova C, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2016 Oct;11(10):1711-7. doi: 10.1016/j.jtho.2016.05.017. Epub 2016 May 31.

25.

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter.

Suda K, Rivard CJ, Mitsudomi T, Hirsch FR.

Cancer Res. 2016 May 15;76(10):3109-10. doi: 10.1158/0008-5472.CAN-15-2916. Epub 2016 May 2. No abstract available.

26.

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.

He Y, Sun W, Wang Y, Ren S, Li X, Li J, Rivard CJ, Zhou C, Hirsch FR.

Onco Targets Ther. 2016 Apr 21;9:2409-14. doi: 10.2147/OTT.S102236. eCollection 2016.

27.

Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel.

Lanaspa MA, Epperson LE, Li N, Cicerchi C, Garcia GE, Roncal-Jimenez CA, Trostel J, Jain S, Mant CT, Rivard CJ, Ishimoto T, Shimada M, Sanchez-Lozada LG, Nakagawa T, Jani A, Stenvinkel P, Martin SL, Johnson RJ.

PLoS One. 2015 Apr 9;10(4):e0123509. doi: 10.1371/journal.pone.0123509. eCollection 2015.

28.

Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study.

Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, Snell-Bergeon JK.

Acta Diabetol. 2014 Oct;51(5):783-91. doi: 10.1007/s00592-014-0611-1. Epub 2014 Jun 15.

29.

Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.

Lanaspa MA, Ishimoto T, Cicerchi C, Tamura Y, Roncal-Jimenez CA, Chen W, Tanabe K, Andres-Hernando A, Orlicky DJ, Finol E, Inaba S, Li N, Rivard CJ, Kosugi T, Sanchez-Lozada LG, Petrash JM, Sautin YY, Ejaz AA, Kitagawa W, Garcia GE, Bonthron DT, Asipu A, Diggle CP, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ.

J Am Soc Nephrol. 2014 Nov;25(11):2526-38. doi: 10.1681/ASN.2013080901. Epub 2014 May 29.

30.

Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids.

Cicerchi C, Li N, Kratzer J, Garcia G, Roncal-Jimenez CA, Tanabe K, Hunter B, Rivard CJ, Sautin YY, Gaucher EA, Johnson RJ, Lanaspa MA.

FASEB J. 2014 Aug;28(8):3339-50. doi: 10.1096/fj.13-243634. Epub 2014 Apr 22.

31.

Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes.

Bjornstad P, Paul Wadwa R, Sirota JC, Snell-Bergeon JK, McFann K, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM.

J Clin Hypertens (Greenwich). 2014 Apr;16(4):283-8. doi: 10.1111/jch.12305. Epub 2014 Mar 26.

32.

Fat storage syndrome in Pacific peoples: a combination of environment and genetics?

Johnson RJ, Lanaspa MA, Sanchez-Lozada LG, Rivard CJ, Bjornstad PS, Merriman T, Sundborn G.

Pac Health Dialog. 2014 Mar;20(1):11-6. Review.

PMID:
25928990
33.

Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes.

Bjornstad P, Snell-Bergeon JK, McFann K, Wadwa RP, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM.

J Diabetes Complications. 2014 May-Jun;28(3):298-304. doi: 10.1016/j.jdiacomp.2013.12.007. Epub 2013 Dec 27.

34.

Fructokinase activity mediates dehydration-induced renal injury.

Roncal Jimenez CA, Ishimoto T, Lanaspa MA, Rivard CJ, Nakagawa T, Ejaz AA, Cicerchi C, Inaba S, Le M, Miyazaki M, Glaser J, Correa-Rotter R, González MA, Aragón A, Wesseling C, Sánchez-Lozada LG, Johnson RJ.

Kidney Int. 2014 Aug;86(2):294-302. doi: 10.1038/ki.2013.492. Epub 2013 Dec 11.

35.

Umami: the taste that drives purine intake.

Johnson RJ, Nakagawa T, Sánchez-Lozada LG, Lanaspa MA, Tamura Y, Tanabe K, Ishimoto T, Thomas J, Inaba S, Kitagawa W, Rivard CJ.

J Rheumatol. 2013 Nov;40(11):1794-6. doi: 10.3899/jrheum.130531. No abstract available.

PMID:
24187156
36.

High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase.

Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ.

Hepatology. 2013 Nov;58(5):1632-43. doi: 10.1002/hep.26594. Epub 2013 Oct 8.

37.

Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes.

Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, Rivard CJ, Araya CE, Saleem MA, Mathieson PW, Johnson RJ, Garin EH.

Pediatr Nephrol. 2013 Sep;28(9):1803-12. doi: 10.1007/s00467-013-2498-4. Epub 2013 May 21.

38.

Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver.

Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, Hunter B, Andrés-Hernando A, Ishimoto T, Sánchez-Lozada LG, Thomas J, Hodges RS, Mant CT, Johnson RJ.

PLoS One. 2012;7(11):e48801. doi: 10.1371/journal.pone.0048801. Epub 2012 Nov 9.

39.

Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver.

Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, Le M, Garcia GE, Thomas JB, Rivard CJ, Andres-Hernando A, Hunter B, Schreiner G, Rodriguez-Iturbe B, Sautin YY, Johnson RJ.

PLoS One. 2012;7(10):e47948. doi: 10.1371/journal.pone.0047948. Epub 2012 Oct 24.

40.

Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice.

Ishimoto T, Lanaspa MA, Le MT, Garcia GE, Diggle CP, Maclean PS, Jackman MR, Asipu A, Roncal-Jimenez CA, Kosugi T, Rivard CJ, Maruyama S, Rodriguez-Iturbe B, Sánchez-Lozada LG, Bonthron DT, Sautin YY, Johnson RJ.

Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4320-5. doi: 10.1073/pnas.1119908109. Epub 2012 Feb 27.

41.

Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1151-60. doi: 10.1152/ajprenal.00596.2011. Epub 2012 Feb 15.

42.

Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects.

Le MT, Frye RF, Rivard CJ, Cheng J, McFann KK, Segal MS, Johnson RJ, Johnson JA.

Metabolism. 2012 May;61(5):641-51. doi: 10.1016/j.metabol.2011.09.013. Epub 2011 Dec 5.

43.

Macrophages mediate lung inflammation in a mouse model of ischemic acute kidney injury.

Altmann C, Andres-Hernando A, McMahan RH, Ahuja N, He Z, Rivard CJ, Edelstein CL, Barthel L, Janssen WJ, Faubel S.

Am J Physiol Renal Physiol. 2012 Feb 15;302(4):F421-32. doi: 10.1152/ajprenal.00559.2010. Epub 2011 Nov 23.

44.

Lecithin-cholesterol acyltransferase (LCAT) deficiency without mutations in the coding sequence: a case report and literature review.

Shoji K, Morita H, Ishigaki Y, Rivard CJ, Takayasu M, Nakayama K, Nakayama T, Inoue Y, Ayaki M, Yoshimura A.

Clin Nephrol. 2011 Oct;76(4):323-8. Review.

PMID:
21955868
45.

Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway.

Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Wymer DT, Yamabe H, Mathieson PW, Saleem MA, Garin EH, Johnson RJ.

Nephrol Dial Transplant. 2012 Jan;27(1):81-9. doi: 10.1093/ndt/gfr271. Epub 2011 May 26.

PMID:
21617192
46.

Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake.

Roncal-Jimenez CA, Lanaspa MA, Rivard CJ, Nakagawa T, Sanchez-Lozada LG, Jalal D, Andres-Hernando A, Tanabe K, Madero M, Li N, Cicerchi C, Mc Fann K, Sautin YY, Johnson RJ.

Metabolism. 2011 Sep;60(9):1259-70. doi: 10.1016/j.metabol.2011.01.008. Epub 2011 Apr 12.

47.

Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking.

Li C, Wang W, Rivard CJ, Lanaspa MA, Summer S, Schrier RW.

Am J Physiol Renal Physiol. 2011 May;300(5):F1255-61. doi: 10.1152/ajprenal.00469.2010. Epub 2011 Feb 16.

48.

Effects of 2-bromoethanamine on TonEBP expression and its possible role in induction of renal papillary necrosis in mice.

Andres-Hernando A, Lanaspa MA, Li N, Cicerchi C, Roncal-Jimenez C, Cantor GH, Sorribas V, Rivard CJ, Berl T.

Toxicol Sci. 2010 Dec;118(2):510-20. doi: 10.1093/toxsci/kfq261. Epub 2010 Sep 7.

49.

The expression of aquaporin-1 in the medulla of the kidney is dependent on the transcription factor associated with hypertonicity, TonEBP.

Lanaspa MA, Andres-Hernando A, Li N, Rivard CJ, Cicerchi C, Roncal-Jimenez C, Schrier RW, Berl T.

J Biol Chem. 2010 Oct 8;285(41):31694-703. doi: 10.1074/jbc.M109.093690. Epub 2010 Jul 16.

50.

Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.

Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ.

Kidney Int. 2010 Aug;78(3):296-302. doi: 10.1038/ki.2010.143. Epub 2010 May 19.

Supplemental Content

Loading ...
Support Center